Summary
Global Markets Direct’s, ‘Enterocolitis - Pipeline Review, H1 2016’, provides an overview of the Enterocolitis pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Enterocolitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Enterocolitis and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Enterocolitis
- The report reviews pipeline therapeutics for Enterocolitis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Enterocolitis therapeutics and enlists all their major and minor projects
- The report assesses Enterocolitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Enterocolitis
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Enterocolitis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Enterocolitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Angothera GmbH
AvidBiotics Corp.
Infant Bacterial Therapeutics AB
Sigma-Tau Pharmaceuticals, Inc
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Enterocolitis Overview 6
Therapeutics Development 7
Pipeline Products for Enterocolitis - Overview 7
Pipeline Products for Enterocolitis - Comparative Analysis 8
Enterocolitis - Therapeutics under Development by Companies 9
Enterocolitis - Therapeutics under Investigation by Universities/Institutes 10
Enterocolitis - Pipeline Products Glance 11
Clinical Stage Products 11
Early Stage Products 12
Enterocolitis - Products under Development by Companies 13
Enterocolitis - Products under Investigation by Universities/Institutes 14
Enterocolitis - Companies Involved in Therapeutics Development 15
Angothera GmbH 15
AvidBiotics Corp. 16
Infant Bacterial Therapeutics AB 17
Sigma-Tau Pharmaceuticals, Inc 18
Enterocolitis - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 25
Drug Profiles 27
Antibodies for Enterocolitis - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
AvR2-V10 - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
C-34 - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
IBP-9414 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
NRG-4 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Recombinant Peptide to Activate Mucin 3 for Enterocolitis and Infectious Diarrhea - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Small Molecules for Necrotizing Enterocolitis - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
STP-206 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Enterocolitis - Recent Pipeline Updates 38
Enterocolitis - Dormant Projects 39
Enterocolitis - Product Development Milestones 40
Featured News & Press Releases 40
Apr 01, 2015: Sigma-Tau Pharmaceuticals Receives Orphan Drug Designation for STP-206 for Prevention of Necrotizing Enterocolitis 40
Feb 04, 2014: Sigma-Tau Pharmaceuticals Announces First Patient Dosed in Phase I/II Clinical Trial of STP206 for Prevention of Necrotizing Enterocolitis in Very Low Birth Weight Premature Infants 40
Apr 07, 2009: Sigma-Tau Partners With Danisco Bioactive To Develop Drug Candidate For Prevention Of Necrotizing Enterocolitis 41
Appendix 42
Methodology 42
Coverage 42
Secondary Research 42
Primary Research 42
Expert Panel Validation 42
Contact Us 42
Disclaimer 43
List of Tables
Number of Products under Development for Enterocolitis, H1 2016 7
Number of Products under Development for Enterocolitis - Comparative Analysis, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Number of Products under Investigation by Universities/Institutes, H1 2016 10
Comparative Analysis by Clinical Stage Development, H1 2016 11
Comparative Analysis by Early Stage Development, H1 2016 12
Products under Development by Companies, H1 2016 13
Products under Investigation by Universities/Institutes, H1 2016 14
Enterocolitis - Pipeline by Angothera GmbH, H1 2016 15
Enterocolitis - Pipeline by AvidBiotics Corp., H1 2016 16
Enterocolitis - Pipeline by Infant Bacterial Therapeutics AB, H1 2016 17
Enterocolitis - Pipeline by Sigma-Tau Pharmaceuticals, Inc, H1 2016 18
Assessment by Monotherapy Products, H1 2016 19
Number of Products by Stage and Target, H1 2016 21
Number of Products by Stage and Mechanism of Action, H1 2016 23
Number of Products by Stage and Route of Administration, H1 2016 24
Number of Products by Stage and Molecule Type, H1 2016 26
Enterocolitis Therapeutics - Recent Pipeline Updates, H1 2016 38
Enterocolitis - Dormant Projects, H1 2016 39
List of Figures
Number of Products under Development for Enterocolitis, H1 2016 7
Number of Products under Development for Enterocolitis - Comparative Analysis, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Number of Products under Investigation by Universities/Institutes, H1 2016 10
Comparative Analysis by Clinical Stage Development, H1 2016 11
Comparative Analysis by Early Stage Products, H1 2016 12
Assessment by Monotherapy Products, H1 2016 19
Number of Products by Targets, H1 2016 20
Number of Products by Stage and Top 10 Targets, H1 2016 20
Number of Products by Mechanism of Actions, H1 2016 22
Number of Products by Stage and Mechanism of Actions, H1 2016 22
Number of Products by Stage and Routes of Administration, H1 2016 24
Number of Products by Molecule Types, H1 2016 25
Number of Products by Stage and Molecule Types, H1 2016 25
